Tests a brain implant that lets people with paralysis control a cursor by thought
Tests a brain-computer device in adults with tetraplegia, with speech and movement loss.
Plain-language title generated from the registry record
Registry title: Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
Key facts
- Where
- Boston and Stanford, United StatesSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05724173, who can take part
Where in United States
- Massachusetts General HospitalBoston, United StatesTaking people
- Stanford University School of MedicineStanford, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Leigh R. Hochberg, MD, PhD.
- Trial code
- NCT05724173
- Record updated
- 2 June 2026
- Original description
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.Read full original descriptionShow less
Single Neuron Population Dynamics in Human Speech Motor Cortex for a Speech Prosthesis
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
Inclusion: Between 18 and 80 years of age; Participants must have a diagnosis of amyotrophic lateral sclerosis (ALS) as verified by a clinical expert in neurologic diseases; Participants with a diagnosis of ALS with anarthria, or severe dysarthria with decline in the preceding four months; Must be within a three-hour drive of the Study site and geographically stable for at least 15 months after enrollment.
Exclusion: Chronic oral or intravenous steroids or immunosuppressive therapy; Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses; Other serious disease or disorder that could seriously affect ability to participate in the study; (There are additional exclusion criteria).